The Networking Support Scheme (NSS) of the European Joint Programme on Rare Diseases is funding quarterly networking initiatives in the field of rare diseases and rare cancers, bringing together health care professionals, researchers, patient advocacy groups, Early Career Scientists and other relevant stakeholders.
There will be a pause in the opening of the Networking Support Scheme until July 1, 2022 when the submission system will be opened again.
You can submit your application from July 1, 2022. Your event should take place between February 15, 2023 and September 1, 2023 due to the final date of the EJP RD.
The last collection dates for the Networking Support Scheme in EJP RD will be September 1, 2022 and December 1, 2022.
The first aim of the Networking Support Scheme in the European Joint Programme on Rare Diseases (EJP RD) is to encourage sharing of knowledge on rare diseases or rare cancers between health care professionals, researchers and patients in new or expanding research networks by funding networking events.The second aim of the Networking Support Scheme is to enable or increase the participation of usually underrepresented countries in Europe in new and in expanding research networks on rare diseases or rare cancers.
Focus of the Networking events
The scheme will provide financial support to applicants to organize workshops or conferences. These workshops or conferences are meant to1. Form new research networks or expand existing research networks;
2. Strengthen collaborations between different stakeholders in different countries;
3. Enable the exchange of knowledge.
4. These workshops or conferences should be (the implications of) research results and innovative solutions. The results of these networking events may lead to future collaborative and novel research efforts.
The aims of the NSS are in compliance with the vision set by the International Rare Diseases Research Consortium (IRDiRC). The IRDiRC vision is: “enable all people living with a rare disease to receive an accurate diagnosis, care, and available therapy within one year of coming to medical attention”.